OTCMKTS:CHSYF China Medical System (CHSYF) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free CHSYF Stock Alerts $0.93 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.93▼$0.9350-Day Range$0.93▼$1.5252-Week Range$0.93▼$0.93VolumeN/AAverage Volume733 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get China Medical System alerts: Email Address Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About China Medical System Stock (OTCMKTS:CHSYF)China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. It also offers DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company provides Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.Read More CHSYF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CHSYF Stock News HeadlinesMay 8, 2024 | msn.comFDA approves CereVasc’s eShunt system study for hydrocephalusMay 7, 2024 | msn.comWorld Street | KKR's health bet, Korean crackdown on shorts, China-France deal talks, Steve Wozniak's space gig and moreMay 11, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 6, 2024 | msn.comEurope live: China’s Xi arrives in Paris with trade and Ukraine on agendaMay 2, 2024 | americanbankingnews.comChina Medical System (OTCMKTS:CHSYF) Shares Down 0.1% May 1, 2024 | finance.yahoo.comAXA partners with Prosper Health to expand "Healthcare and Wellness Ecosystem" in ChinaMay 1, 2024 | uk.finance.yahoo.comQ1 2024 Merit Medical Systems Inc Earnings CallMay 1, 2024 | msn.comMerit Medical Systems, Inc. (NASDAQ:MMSI) Q1 2024 Earnings Call TranscriptMay 11, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.April 30, 2024 | msn.comChina's Top Anti-Spy Agency Vows To 'Fight Any Form Of Taiwan Independence Moves' Before Presidential InaugurationApril 29, 2024 | reuters.comWhat is Tesla's Full Self-Driving and why its China rollout mattersApril 28, 2024 | msn.comMan behind China’s first approved Covid-19 shot expelled from national legislatureApril 28, 2024 | msn.comChina embraces AI boomApril 26, 2024 | yahoo.comDay 4 of witness testimonies underway in Trump’s hush money trialApril 24, 2024 | msn.comChina Faces New EU Subsidy Probes Days Before Xi VisitApril 23, 2024 | msn.comChina-US relations stable despite US 'interference', Chinese official saysApril 23, 2024 | finance.yahoo.comChina Medical System: New Drug Application of Desidustat Tablets Accepted in ChinaApril 16, 2024 | msn.comEU to reportedly start China probe over medical device procurementApril 14, 2024 | seekingalpha.comGold's Battle Royale: Inflation Vs. Interest RatesApril 12, 2024 | msn.comPilot door-to-door hospital transfers from mainland China and Macau will not be two-way street at first, health secretary saysApril 12, 2024 | msn.comMiddle East crisis live: Israel warns it will hit back if Iran strikes as US issues travel restrictions for diplomatsApril 9, 2024 | ft.comLive news: Trafigura chief points to ‘real problem’ for critical minerals as demand risesApril 9, 2024 | msn.comRussia-Ukraine war – live: Moscow claims China ties at all time high as Cameron in US to urge support for KyivApril 5, 2024 | msn.comWhat's behind China's gold-buying spree?April 3, 2024 | msn.comChina and Iran will cheer if Ukraine fails, warns Lord CameronMarch 31, 2024 | msn.comUs tightens restrictions on export of AI chips to China: What's the reasonMarch 30, 2024 | finance.yahoo.comChina Medical University Hospital (CMUH) Developing iDREAM to Detect Sleep Apnea at HomeSee More Headlines Receive CHSYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for China Medical System and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:CHSYF CUSIPN/A CIKN/A Webwww.cms.net.cn Phone852-2369-7678FaxN/AEmployees4,400Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Kong Lam (Age 59)Founder, Chairman, CEO & President Comp: $762.79kMs. Yanling Chen (Age 54)CFO, VP & Executive Director Comp: $481.08kMr. Hongbing Chen (Age 57)COO, VP, Director of Sales & Marketing and Executive Director Comp: $664.28kMs. Sanyan Wu (Age 41)Director of Legal Department & Company Secretary Dr. Huaizheng Peng M.D. (Age 62)Ph.D., Chief Business Officer Mr. Fei JiangChief Investment Officer of Greater ChinaMr. James Patrick Stearns (Age 45)Chief Investment Officer of Europe & America More ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors CHSYF Stock Analysis - Frequently Asked Questions Should I buy or sell China Medical System stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for China Medical System in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHSYF shares. View CHSYF analyst ratings or view top-rated stocks. How have CHSYF shares performed in 2024? China Medical System's stock was trading at $1.5180 at the beginning of 2024. Since then, CHSYF stock has decreased by 38.7% and is now trading at $0.9307. View the best growth stocks for 2024 here. Are investors shorting China Medical System? China Medical System saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,881,800 shares, an increase of 358.1% from the April 15th total of 410,800 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is currently 18,818.0 days. View China Medical System's Short Interest. How do I buy shares of China Medical System? Shares of CHSYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CHSYF) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Medical System Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.